{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:28Z","timestamp":1787026948844,"version":"build-2736575974"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thrombocytopenia (TP) is a rare adverse event (&amp;lt;1%) associated with immune checkpoint inhibitor (ICI) therapy, termed immunotherapy-related thrombocytopenia (irTP). This condition is particularly concerning in patients with metastatic bone cancer due to the increased risk of life-threatening bleeding complications, which may further compromise patient management. Moreover, the scarcity of systematic reports on irTP in this population underscores the need for focused investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the clinical records of patients with metastatic bone cancer who received single-agent ICI therapy\u2014specifically, PD-1 inhibitors such as pembrolizumab, penpulimab, and sintilimab\u2014between May 2020 and December 2024 at three tertiary hospitals. Patients who developed severe irTP were included in the analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 94 cases were screened, of which 7 patients (7.45%) were diagnosed with severe irTP. The primary cancer subtypes included melanoma (n\u00a0= 4), undifferentiated pleomorphic sarcoma (n = 2), and renal clear cell carcinoma (n = 1). All seven patients were undergoing combination therapy with the bone anti-resorptive agent denosumab. The median time to irTP onset was 92 days after the initial ICI administration. Following diagnosis, all patients were hospitalized and received intensive immunomodulatory therapy, supportive care, and meticulous nursing management. While symptoms significantly improved in all cases, long-term follow-up indicated that patients remained stable after discharge. The median duration of hospitalization was 18 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although irTP is considered rare in the literature, we observed an incidence of 7.45% in our cohort, highlighting a significant clinical concern due to the potential for severe bleeding complications in metastatic bone cancer patients. Timely diagnosis and comprehensive treatment\u2014supported by interdisciplinary collaboration among oncologists, hematologists, and nursing staff\u2014are essential for achieving full recovery. Furthermore, our findings emphasize the need for future research into predictive biomarkers and risk factors for irTP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1574379","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T01:23:04Z","timestamp":1748308984000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Severe immunotherapy-related thrombocytopenia in metastatic bone cancer: a multicenter retrospective case series highlighting early recognition and management"],"prefix":"10.3389","volume":"15","author":[{"given":"Qian","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaonong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianshui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","article-title":"Progress in systemic therapy for advanced-stage urothelial carcinoma","volume":"21","author":"Nadal","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.245","article-title":"Mitigating the toxic effects of anticancer immunotherapy","volume":"11","author":"Gangadhar","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184369","article-title":"Management of immune-related adverse events from immune-checkpoint inhibitors in advanced or metastatic renal cell carcinoma","volume":"14","author":"Leucht","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113446","article-title":"Multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors","volume":"12","author":"Londono","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009063","article-title":"Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111606","article-title":"PD-1\/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review","volume":"129","author":"Moore","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010098","article-title":"Advances in cell and immune therapies for melanoma","volume":"13","author":"Timis","year":"2025","journal-title":"Biomedicines"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","article-title":"Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review","volume":"101","author":"Ghanem","year":"2022","journal-title":"Ann Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1188\/17.CJON.S4.42-51","article-title":"PD-1 inhibitor therapy: consensus statement from the faculty of the melanoma nursing initiative on managing adverse events","volume":"21","author":"McGettigan","year":"2017","journal-title":"Clin J Oncol Nurs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050770","article-title":"Impact of glucocorticoid use in oncology in the immunotherapy era","volume":"11","author":"Kalfeist","year":"2022","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050413","article-title":"The use of immune regulation in treating head and neck squamous cell carcinoma (HNSCC)","volume":"13","author":"Wang","year":"2024","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010034","article-title":"Emerging immunotherapy approaches for advanced clear cell renal cell carcinoma","volume":"13","author":"Meng","year":"2023","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced melanoma","volume":"8","author":"van Not","year":"2022","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cnur.2020.02.007","article-title":"Excellence in patient education: evidence-based education that \u201cSticks\u201d and improves patient outcomes","volume":"55","author":"Cutilli","year":"2020","journal-title":"Nurs Clin North Am"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1574379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T01:23:04Z","timestamp":1748308984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1574379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":22,"alternative-id":["10.3389\/fonc.2025.1574379"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1574379","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"article-number":"1574379"}}